Venous thromboembolism (VTE) is a multifactorial disease, and its risk depends on exposure to risk factors and predisposing conditions. Based on their strength of association with a VTE episode, risk factors are classified as major or minor and determined using a temporal pattern to be transient or persistent. All patients with VTE should receive anticoagulant treatment for at least 3 months in the absence of an absolute contraindication. Beyond this period, selected patients may be candidates for an extended phase of anticoagulation aimed at secondary VTE prevention. The risk of recurrent VTE if anticoagulation is discontinued is probably the main driver of decision-making regarding extended treatment. The risk of recurrence after VTE associated with major risk factors is low if the risk factor is no longer present. In this case, treatment can be discontinued. If the major risk factor is persistent, anticoagulation should be continued. After VTE occurring in the absence of risk factors, anticoagulation should probably be continued indefinitely if the risk for bleeding is low and preferably with minimal effective doses of anticoagulants. VTE occurring after exposure to minor risk factors is probably the most challenging situation, especially if the clinical manifestation was acute pulmonary embolism. Understanding the actual role of minor risk factors in the occurrence of VTE helps in estimating the risk of recurrence and avoiding the dangers associated with unnecessary anticoagulation. The availability of safer strategies for anticoagulation could allow personalized strategies for secondary prevention of VTE.

1.
Centers for Disease Control and Prevention
.
Venous thromboembolism in adult hospitalizations—United States, 2007-2009
.
MMWR Morb Mortal Wkly Rep
.
2012
;
61
(
22
):
401
-
404
. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6122a1.htm. Accessed
5
October
2023
.
2.
Martinez
C
,
Cohen
AT
,
Bamber
L
,
Rietbrock
S.
Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer
.
Thromb Haemost
.
2014
;
112
(
2
):
255
-
263
.
doi:10.1160/TH13-09-0793
.
3.
Huang
W
,
Goldberg
RJ
,
Anderson
FA
,
Kiefe
CI
,
Spencer
FA
.
Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009)
.
Am J Med
.
2014
;
127
(
9
):
829
-
839.e5839e5
.
doi:10.1016/j.amjmed.2014.03.041
.
4.
Monreal
M
,
Agnelli
G
,
Chuang
LH
, et al.
Deep vein thrombosis in Europe—health-related quality of life and mortality
.
Clin Appl Thromb Hemost
.
2019
;
25
(
4
):
107602961988394
.
doi:10.1177/1076029619883946
.
5.
Zuin
M
,
Bikdeli
B
,
Armero
A
, et al.
Trends in pulmonary embolism deaths among young adults aged 25 to 44 years in the United States, 1999 to 2019
.
Am J Cardiol
.
2023
;
202
(
1 September
):
169
-
175
.
doi:10.1016/j.amjcard.2023.06.075
.
6.
Piazza
G.
Walking the tightrope: a balanced discussion of the benefits and harms of extended duration anticoagulation for venous thrombo-embolism
.
Eur Heart J
.
2023
;
44
(
14
):
1245
-
1247
.
doi:10.1093/eurheartj/ehac731
.
7.
Ortel
TL
,
Neumann
I
,
Ageno
W
, et al.
American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: treatment of deep vein thrombosis and pulmonary embolism
.
Blood Adv
.
2020
;
4
(
19
):
4693
-
4738
.
doi:10.1182/bloodadvances.2020001830
.
8.
Stevens
SM
,
Woller
SC
,
Kreuziger
LB
, et al.
Antithrombotic therapy for VTE disease: second update of the CHEST Guideline and Expert Panel Report
.
Chest
.
2021
;
160
(
6
):
e545
-
e608
.
doi:10.1016/j.chest.2021.07.055
.
9.
Becattini
C
,
Agnelli
G
,
Maggioni
AP
, et al
;
COPE Investigators
.
Contemporary management and clinical course of acute pulmonary embolism: the COPE study
.
Thromb Haemost
.
2023
;
123
(
6
):
613
-
626
.
doi:10.1055/a-2031-3859
.
10.
Ageno
W
,
Haas
S
,
Weitz
JI
, et al
;
GARFIELD-VTE Investigators
.
Characteristics and management of patients with venous thromboembolism: the GARFIELD-VTE registry
.
Thromb Haemost
.
2019
;
119
(
2
):
319
-
327
.
doi:10.1055/s-0038-1676611
.
11.
Lutsey
PL
,
Zakai
NA
.
Epidemiology and prevention of venous thromboembolism
.
Nat Rev Cardiol
.
2023
;
20
(
4
):
248
-
262
.
doi:10.1038/s41569-022-00787-6
.
12.
Anderson
DR
,
Morgano
GP
,
Bennett
C
, et al.
American Society of Hematology 2019 Guidelines for Management of Venous Thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients
.
Blood Adv
.
2019
;
3
(
23
):
3898
-
3944
.
doi:10.1182/bloodadvances.2019000975
.
13.
Nemeth
B
,
Cannegieter
SC
.
Venous thrombosis following lower-leg cast immobilization and knee arthroscopy: from a population-based approach to individualized therapy
.
Thromb Res
.
2019
;
174
(
suppl 1
):
62
-
75
.
doi:10.1016/j.thromres.2018.11.030
.
14.
Grewal
K
,
Atzema
CL
,
Sutradhar
R
, et al.
Venous thromboembolism in patients discharged from the emergency department with ankle fractures: a population-based cohort study
.
Ann Emerg Med
.
2022
;
79
(
1
):
35
-
47
.
doi:10.1016/j.annemergmed.2021.06.017
.
15.
Douillet
D
,
Chapelle
C
,
Ollier
E
,
Mismetti
P
,
Roy
PM
,
Laporte
S.
Prevention of venous thromboembolic events in patients with lower leg immobilization after trauma: systematic review and network meta-analysis with meta- epidemiological approach
.
PLoS Med
.
2022
;
19
(
7
):
e1004059
.
doi:10.1371/journal.pmed.1004059
.
16.
Darzi
AJ
,
Karam
SG
,
Charide
R
, et al.
Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta- analysis
.
Blood
.
2020
;
135
(
20
):
1788
-
1810
.
doi:10.1182/blood.2019003603
.
17.
Verso
M
,
Muñoz
A
,
Connors
JM
.
Ambulatory cancer patients: who should definitely receive antithrombotic prophylaxis and who should never receive
.
Intern Emerg Med
.
2023
;
18
(
6
):
1619
-
1634
.
doi:10.1007/s11739-023-03306-8
.
18.
Kuipers
S
,
Cannegieter
SC
,
Middeldorp
S
,
Robyn
L
,
Büller
HR
,
Rosendaal
FR
.
The absolute risk of venous thrombosis after air travel: a cohort study of 8,755 employees of international organisations
.
PLoS Med
.
2007
;
4
(
9
):
e290
.
doi:10.1371/journal.pmed.0040290
.
19.
Hotoleanu
C.
Association between obesity and venous thromboembolism
.
Med Pharm Rep
.
2020
;
93
(
2
):
162
-
168
.
doi:10.15386/mpr-1372
.
20.
Chan
N
,
Xu
K.
Risk factors for venous thromboembolism in women of childbearing age [published online ahead of print 28 July 2023]
.
Thromb Haemost
.
doi:10.1055/a-2125-3290
.
21.
Dragoman
MV
,
Tepper
NK
,
Fu
R
,
Curtis
KM
,
Chou
R
,
Gaffield
ME
.
A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception
.
Intl J Gynecol Amp; Obs
.
2018
;
141
(
3
):
287
-
294
.
doi:10.1002/ijgo.12455
.
22.
Kearon
C
,
Ageno
W
,
Cannegieter
SC
, et al
;
Subcommittees on Control of Anticoagulation, and Predictive and Diagnostic Variables in Thrombotic Disease
.
Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH
.
J Thromb Haemost
.
2016
;
14
(
7
):
1480
-
1483
.
doi:10.1111/jth.13336
.
23.
Le Mao
R
,
Orione
C
,
de Moreuil
C
, et al.
Risk stratification for predicting recurrent venous thromboembolism after discontinuation of anticoagulation: a post hoc analysis of a French prospective multicentre study
.
Eur Respir J
.
2022
;
60
(
3
):
2103002
.
doi:10.1183/13993003.03002-2021
.
24.
Khan
F
,
Tritschler
T
,
Kahn
SR
,
Rodger
MA
.
Venous thromboembolism
.
Lancet
.
2021
;
398
(
10294
):
64
-
77
.
doi:10.1016/S0140-6736(20)32658-1
.
25.
Khan
F
,
Rahman
A
,
Carrier
M
, et al
;
MARVELOUS Collaborators
.
Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis
.
BMJ
.
2019
;
366
(
July
):
l4363
.
doi:10.1136/bmj.l4363
.
26.
Chua
CC
,
Lim
HY
,
Tacey
M
,
Nandurkar
H
,
Ho
P.
Retrospective evaluation of venous thromboembolism: are all transient provoking events the same?
Eur J Haematol
.
2017
;
99
(
1
):
18
-
26
.
doi:10.1111/ejh.12884
.
27.
Abdulrehman
J
,
Elbaz
C
,
Aziz
D
, et al.
Recurrence after stopping anticoagulants in women with combined oral contraceptive-associated venous thromboembolism: a systematic review and meta-analysis
.
Br J Haematol
.
2022
;
199
(
1
):
130
-
142
.
doi:10.1111/bjh.18331
.
28.
Weitz
JI
,
Farjat
AE
,
Ageno
W
, et al
;
GARFIELD-VTE Investigators
.
Influence of body mass index on clinical outcomes in venous thromboembolism: insights from GARFIELD-VTE
.
J Thromb Haemost
.
2021
;
19
(
12
):
3031
-
3043
.
doi:10.1111/jth.15520
.
29.
Timp
JF
,
Braekkan
SK
,
Lijfering
WM
, et al.
Prediction of recurrent venous thrombosis in all patients with a first venous thrombotic event: the Leiden Thrombosis Recurrence Risk Prediction model (L-TRRiP)
.
PLoS Med
.
2019
;
16
(
10
):
e1002883
.
doi:10.1371/journal.pmed.1002883
.
30.
Konstantinides
SV
,
Meyer
G
,
Becattini
C
, et al
;
European Society of Cardiology Scientific Document Group
.
2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)
.
Eur Heart J
.
2020
;
41
(
4
):
543
-
603
.
doi:10.1093/eurheartj/ehz405
.
31.
National Institute for Health and Care Excellence
.
Venous Thromboembolic Diseases: Diagnosis, Management and Thrombophilia Testing. NICE Clinical Guidelines no. 18
.
London
:
NICE
;
2023
.
32.
Carrier
M
,
Le Gal
G
,
Wells
PS
,
Rodger
MA
.
Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism
.
Ann Intern Med
.
2010
;
152
(
9
):
578
-
589
.
doi:10.7326/0003-4819-152-9-201005040-00008
.
33.
Khan
F
,
Tritschler
T
,
Le Gal
G
,
Fergusson
DA
,
Rodger
MA
.
Long-term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism: a systematic review and meta-analysis
.
Ann Intern Med
.
2021
;
174
(
10
):
1420
-
1429
.
doi:10.7326/M21-1094
.
34.
Ageno
W
,
Farjat
A
,
Haas
S
, et al.
Provoked versus unprovoked venous thromboembolism: findings from GARFIELD-VTE
.
Res Pract Thromb Haemost
.
2021
;
5
(
2
):
326
-
341
.
doi:10.1002/rth2.12482
.
35.
Joyce
E
,
Haymart
B
,
Kong
X
, et al.
Length of anticoagulation in provoked venous thromboembolism: a multicenter study of how real-world practice mirrors guideline recommendations
.
J Am Heart Assoc
.
2022
;
11
(
21
):
e025471
.
doi:10.1161/JAHA.122.025471
.
36.
Klok
FA
,
Ageno
W
,
Ay
C
, et al.
Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society
.
Eur Heart J
.
2022
;
43
(
3
):
183
-
189
.
doi:10.1093/eurheartj/ehab816
.
37.
Agnelli
G
,
Buller
HR
,
Cohen
A
, et al
;
AMPLIFY-EXT Investigators
.
Apixaban for extended treatment of venous thromboembolism
.
N Engl J Med
.
2013
;
368
(
8
):
699
-
708
.
doi:10.1056/NEJMoa1207541
.
38.
Weitz
JI
,
Lensing
AWA
,
Prins
MH
, et al
;
EINSTEIN CHOICE investigators
.
Rivaroxaban or aspirin for extended treatment of venous thromboembolism
.
N Engl J Med
.
2017
;
376
(
13
):
1211
-
1222
.
doi:10.1056/nejmoa1700518
.
39.
Albertsen
IE
,
Nielsen
PB
,
Søgaard
M
, et al.
Risk of recurrent venous thromboembolism: a Danish nationwide cohort study
.
Am J Med
.
2018
;
131
(
9
):
1067
-
1074.e41074e4
.
doi:10.1016/j.amjmed.2018.04.042
.
40.
de Winter
MA
,
Büller
HR
,
Carrier
M
, et al
;
VTE-PREDICT Study Group
.
Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score
.
Eur Heart J
.
2023
;
44
(
14
):
1231
-
1244
.
doi:10.1093/eurheartj/ehac776
.
41.
Middeldorp
S
,
Nieuwlaat
R
,
Baumann Kreuziger
L
, et al.
American Society of Hematology 2023 Guidelines for Management of Venous Thromboembolism: thrombophilia testing [published online ahead of print 17 May 2023]
.
Blood Adv
.
doi.org/10.1182/bloodadvances.2023010177
.
42.
Bikdeli
B
,
Hogan
H
,
Morrison
RB
, et al.
Extended-duration low-intensity apixaban to prevent recurrence in patients with provoked venous thromboembolism and enduring risk factors: rationale and design of the HI-PRO trial
.
Thromb Haemost
.
2022
;
122
(
06
):
1061
-
1070
.
doi:10.1055/a-1646-2244
.
43.
De Caterina
R
,
Prisco
D
,
Eikelboom
JW
.
Factor XI inhibitors: cardiovascular perspectives
.
Eur Heart J
.
2023
;
44
(
4
):
280
-
292
.
doi:10.1093/eurheartj/ehac464
.
You do not currently have access to this content.